Okla. lawmakers may challenge veto on bill to jail physicians for abortions

John Gregory | | Health Exec | Policy & Regulations

Despite being vetoed by Republican Okla. Gov. Mary Fallin, state legislation to imprison and strip medical licenses from physicians who perform abortions isn’t dead yet.

To hear more about what may lead the sponsoring legislator to go against a chief executive from his own party, click on the link below:  

Oklahoma senator weighing options after abortion ban veto

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Related Content

Veterans Affairs denies it discriminates based on politics, marital status
Dexcom recalls more than 2 million CGM receivers over safety issues—dozens of adverse events reported
Ivenix infusion kits recalled by FDA due to serious manufacturing defect
FDA recalls pediatric breathing kits after eight serious injuries
Judge rips Trump administration for terminating DEI-advancing NIH grants: ‘Have we no shame?’
FDA recalls Zyno infusion pumps, citing risk of death

Around the web

Cardiovascular Business
Eli Lilly to acquire gene-editing specialists focused on CVD for up to $1.3B

The company has agreed to acquire Verve Therapeutics for an upfront payment of approximately $1 billion. The total could increase significantly, however, if certain milestones are met. One of Verve's biggest gene therapies has already received the FDA's fast track designation.

Cardiovascular Business
AMA House of Delegates helps cardiology groups influence healthcare policies

American College of Cardiology Board of Governors Chair David E. Winchester, MD, MS, examines the many benefits of working with the American Medical Association House of Delegates to bring about significant change.

Cardiovascular Business
Smaller revenues, less growth: In US, tariffs may create headaches for $34.5B cardiovascular device market

“Without a more concrete and stable policy on these tariffs from the current American administration, it is likely that most manufacturers will be forced to continuously change their internal forecasts and production plans," one analyst said.